A carregar...
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
INTRODUCTION: In the phase 3 PACIFIC study of patients with unresectable stage III NSCLC without progression after chemoradiotherapy, durvalumab demonstrated significant improvements versus placebo in the primary end points of progression-free survival (hazard ratio [HR] = 0.52, 95% confidence inter...
Na minha lista:
| Publicado no: | J Thorac Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7244187/ https://ncbi.nlm.nih.gov/pubmed/31622733 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2019.10.002 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|